https://www.selleckchem.com/pr....oducts/recilisib.htm
To assess the prognostic value of the ChOLE classification in predicting the severity of acquired cholesteatoma. A retrospective chart review of patients undergoing primary cholesteatoma surgery in our tertiary referral center. The primary outcome measures were analyzed in three groups of follow up (FU) residual cholesteatoma in group A, FU 52 weeks after last-look surgery or MRI-DWI; recurrent cholesteatoma in group B, FU 52 weeks after last outpatient visit; and adverse events (AE) in group C, FU 12 weeks after surger
Like
Comment
Share
